No Data
No Data
A Great Week for Institutional Investors Who Own 54% of Oruka Therapeutics, Inc. (NASDAQ:ORKA)
Oruka Therapeutics (ORKA) Gets a Buy From TD Cowen
Promising Potential of Oruka Therapeutics' ORKA-001 in Psoriasis Treatment
Oruka Therapeutics: Strong Q3 and Strategic Advances
Top Premarket Gainers
H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $45
Stock_Drift : It’s not allowed north of the Mason Dixon line. Same with sugar in tea and Waffle Houses.
Stock_Drift : And I’m just kidding around.
MARKET-TEST-DUMMY OP Stock_Drift : Damn, that stings a little.
MARKET-TEST-DUMMY OP Stock_Drift : Absolutely! Enjoy it!
Stock_Drift MARKET-TEST-DUMMY OP : Just fun banter, I love the south, except Georgia.
View more comments...